𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study

✍ Scribed by Mónica Guevara; Carlos Terra; André Nazar; Elsa Solà; Javier Fernández; Marco Pavesi; Vicente Arroyo; Pere Ginès

Book ID
116652831
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
713 KB
Volume
57
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Albumin for bacterial infections other t
Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study
✍ Mónica Guevara; Carlos Terra; André Nazar; Elsa Solà; Javier Fernández; Marco Pa 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 713 KB

Background & Aims: Treatment with albumin in patients with cirrhosis and spontaneous bacterial peritonitis (SBP) prevents renal failure and improves survival. Whether albumin has similar beneficial effects in patients with infections other than SBP is unknown. Methods: One hundred and ten patients w

A randomized unblinded pilot study compa
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis
✍ Javier Fernández; Joan Monteagudo; Xavier Bargallo; Wladimiro Jiménez; Jaume Bos 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

The administration of albumin improves circulatory function, prevents hepatorenal syndrome, and reduces hospital mortality in patients with cirrhosis and spontaneous bacterial peritonitis. This randomized unblinded pilot study compared the effect of albumin (10 patients) and the synthetic plasma exp

Two different dosages of cefotaxime in t
Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study
✍ Antoni Rimola; Joan M. Salmerón; Gerardo Clemente; Luis Rodrigo; Antoni Obrador; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 741 KB

Cefotaxime (CTX) is considered one of the first-choice antibiotics in the therapy of spontaneous bacterial peritonitis (SBP) in cirrhosis. Because CTX is largely metabolized in the liver, this drug may also be effective in SBP by administering lower doses than those habitually used. To investigate t